Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$10.56
-6.3%
$12.31
$10.59
▼
$17.31
$222.39M0.8176,535 shs161,443 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.90
+7.2%
$2.07
$1.64
▼
$4.53
$64.01M1.27586,737 shs648,917 shs
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$0.85
-8.3%
$1.39
$0.84
▼
$2.86
$152.21M1.613.57 million shs2.63 million shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$3.45
-6.1%
$4.38
$3.42
▼
$9.94
$208.32M0.741.47 million shs1.07 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-3.51%-1.92%-20.09%-33.69%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-5.66%-10.40%-8.09%-37.87%-31.42%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-1.55%-18.82%-35.29%-55.93%-57.35%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-2.13%-7.09%-11.99%-30.49%-28.60%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amarin Corporation PLC stock logo
AMRN
Amarin
$10.56
-6.3%
$12.31
$10.59
▼
$17.31
$222.39M0.8176,535 shs161,443 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.90
+7.2%
$2.07
$1.64
▼
$4.53
$64.01M1.27586,737 shs648,917 shs
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$0.85
-8.3%
$1.39
$0.84
▼
$2.86
$152.21M1.613.57 million shs2.63 million shs
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$3.45
-6.1%
$4.38
$3.42
▼
$9.94
$208.32M0.741.47 million shs1.07 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amarin Corporation PLC stock logo
AMRN
Amarin
0.00%-3.51%-1.92%-20.09%-33.69%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-5.66%-10.40%-8.09%-37.87%-31.42%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-1.55%-18.82%-35.29%-55.93%-57.35%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-2.13%-7.09%-11.99%-30.49%-28.60%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amarin Corporation PLC stock logo
AMRN
Amarin
1.33
Sell$13.0023.16% Upside
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.25
Hold$17.00796.15% Upside
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
3.00
Buy$9.00960.07% Upside
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
2.56
Moderate Buy$13.50291.87% Upside

Current Analyst Ratings Breakdown

Latest FBIO, VNDA, PALI, and AMRN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
Initiated CoverageHold
11/11/2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
Lower Price TargetBuy$5.00
11/4/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
UpgradeStrong Sell ➝ Hold
11/3/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
DowngradeStrong-Buy ➝ Hold
11/2/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Reiterated RatingBuy
10/23/2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
DowngradeHold (C-) ➝ Sell (D+)
10/21/2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
Reiterated RatingOutperform
10/15/2026
Amarin Corporation PLC stock logo
AMRN
Amarin
Reiterated RatingSell (D-)
10/15/2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
Reiterated RatingSell (D-)
10/13/2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
Reiterated RatingBuy$7.00
10/12/2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
Reiterated RatingSell (E+)
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amarin Corporation PLC stock logo
AMRN
Amarin
$213.65M1.04$0.34 per share31.19$21.09 per share0.50
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$63.26M1.01N/AN/A$5.25 per share0.36
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
$250K608.83N/AN/A$0.63 per share1.35
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
$216.10M0.96N/AN/A$3.31 per share1.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amarin Corporation PLC stock logo
AMRN
Amarin
-$38.80M-$0.96N/AN/AN/A-10.87%-0.52%-0.36%N/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$6.82M$2.300.820.80N/A143.04%61.84%35.15%N/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$16.78M-$0.48N/AN/AN/AN/A-35.60%-34.04%N/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$220.47M-$4.62N/AN/AN/A-119.87%-62.70%-37.53%N/A

Latest FBIO, VNDA, PALI, and AMRN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/13/2026Q3 2026
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$0.27-$0.23+$0.04-$0.23$21.58 million$19.16 million
11/10/2026Q3 2026
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
-$0.0610-$0.07-$0.0090-$0.07N/AN/A
10/28/2026Q3 2026
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
-$0.6820-$0.37+$0.3120-$0.37$69.20 million$69.82 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Amarin Corporation PLC stock logo
AMRN
Amarin
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
N/AN/AN/AN/AN/A
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amarin Corporation PLC stock logo
AMRN
Amarin
N/A
3.50
2.59
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
0.10
2.93
3.83
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
N/A
20.16
20.16
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
0.01
1.54
1.53

Institutional Ownership

CompanyInstitutional Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
22.25%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
11.79%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
88.14%

Insider Ownership

CompanyInsider Ownership
Amarin Corporation PLC stock logo
AMRN
Amarin
4.21%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
28.50%
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
0.07%
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
10.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amarin Corporation PLC stock logo
AMRN
Amarin
8021.07 million20.19 millionOptionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
7833.74 million24.13 millionOptionable
Palisade Bio, Inc. stock logo
PALI
Palisade Bio
14179.28 million179.15 millionNot Optionable
Vanda Pharmaceuticals Inc. stock logo
VNDA
Vanda Pharmaceuticals
53360.47 million54.00 millionOptionable

Recent News About These Companies

Vanda Pharmaceuticals Earnings Call Signals Growth Amid Risks
Vanda (VNDA) Q3 2026 Earnings Call Transcript
Vanda Pharmaceuticals Q3 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amarin stock logo

Amarin NASDAQ:AMRN

$10.56 -0.71 (-6.26%)
Closing price 03:59 PM Eastern
Extended Trading
$10.56 +0.01 (+0.05%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.90 +0.13 (+7.18%)
Closing price 03:59 PM Eastern
Extended Trading
$1.90 +0.00 (+0.16%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Palisade Bio stock logo

Palisade Bio NASDAQ:PALI

$0.85 -0.08 (-8.26%)
Closing price 03:58 PM Eastern
Extended Trading
$0.85 +0.01 (+0.59%)
As of 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

Vanda Pharmaceuticals stock logo

Vanda Pharmaceuticals NASDAQ:VNDA

$3.44 -0.23 (-6.13%)
Closing price 03:59 PM Eastern
Extended Trading
$3.44 0.00 (0.00%)
As of 04:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.